Cargando…
Preliminary Clinical Investigation of Combinatorial Pharmacogenomic Testing for the Optimized Treatment of Depression: A Randomized Single-Blind Study
This study aims to explore the potential benefits of antidepressant drugs related to metabolic enzyme and drug-targeted genes, identify the optimal treatment of major depression, and provide a reference for individualized medication selection. A prospective randomized single-blind investigation was...
Autores principales: | Shan, Xiaoxiao, Zhao, Wenli, Qiu, Yan, Wu, Haishan, Chen, Jindong, Fang, Yiru, Guo, Wenbin, Li, Lehua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6753896/ https://www.ncbi.nlm.nih.gov/pubmed/31572113 http://dx.doi.org/10.3389/fnins.2019.00960 |
Ejemplares similares
-
Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient- and rater-blinded, randomized, controlled trial
por: Tiwari, Arun K., et al.
Publicado: (2022) -
Correction: Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient- and rater-blinded, randomized, controlled trial
por: Tiwari, Arun K., et al.
Publicado: (2022) -
Tranylcypromine Causes Neurotoxicity and Represses BHC110/LSD1 in Human-Induced Pluripotent Stem Cell-Derived Cerebral Organoids Model
por: Huang, Jing, et al.
Publicado: (2017) -
Use of combinatorial pharmacogenomic testing in two cases from community psychiatry
por: Fields, Eve S, et al.
Publicado: (2016) -
The clinical validity and utility of combinatorial pharmacogenomics: Enhancing patient outcomes
por: Benitez, Joachim, et al.
Publicado: (2015)